Argenx's ADHERE Study Published In The Lancet Neurology, Showcasing VYVGART Hytrulo's Impact On Reducing CIDP Relapse And Disease Progression
Argenx's ADHERE Study Published In The Lancet Neurology, Showcasing VYVGART Hytrulo's Impact On Reducing CIDP Relapse And Disease Progression
Argenx的ADHERE研究已發表在《柳葉刀神經病學》雜誌上，展示了VYVGARt Hytrulo對減少CIDP復發和疾病進展的影響。
- ADHERE was largest and most innovative clinical trial of CIDP patients to date
- VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action
- VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker FDA-approved to treat CIDP
- ADHERE是迄今爲止CIDP患者最大、最具創新性的臨床試驗。
- VYVGARt Hytrulo（efgartigimod alfa和透明質酶-qvfc）表現出減少疾病進展、降低復發風險和快速發揮作用。
- VYVGARt Hytrulo是首個並且唯一一個經FDA批准用於治療CIDP的新生兒Fc受體（FcRn）阻斷劑。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。